Novo's Obesity Pill: 13% Weight Loss Achieved in Clinical Trials
Novo's Obesity Pill Achieves Remarkable Results
In recent clinical trials, Novo Nordisk presented findings that highlight a significant 13% weight loss achieved by patients on the investigational pill, amycretin, after just twelve weeks. This result was disclosed during the European Association for the Study of Diabetes (EASD) conference, and was described by investigators as remarkable.
Competitive Landscape in Obesity Treatments
This achievement comes amidst a fierce competition in the obesity market, particularly against promising developments from competitors like Terns Pharmaceuticals, Eli Lilly, and Pfizer. Analysts noted that while Terns' TERN-601 achieved a 4.9% weight loss, Novo’s amycretin outperformed significantly.
- The treatment was well-tolerated with mostly mild to moderate adverse events.
- The study included participants with a BMI of 25 to 39 without diabetes.
- Further investigations are planned to explore the long-term potential of amycretin.
Next Steps for Novo Nordisk
Novo’s pipeline also includes the combination therapy CagriSema, which will provide Phase III results soon, showcasing the company’s commitment to advancing obesity treatment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.